COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #82 of 230
7/10 Late treatment study
Cravedi et al., American Journal of Transplantation, doi:10.1111/ajt.16185 (Peer Reviewed)
COVID‐19 and kidney transplantation: Results from the TANGO International Transplant Consortium
Source   PDF   Share   Tweet
Analysis of 144 hospitalized kidney transplant patients showing HCQ mortality HR 1.53, p = 0.17. Subject to confounding by indication.

Cravedi et al., 7/10/2020, retrospective, USA, multiple countries, North America, multiple regions, peer-reviewed, mean age 60.0, 25 authors.
risk of death, 53.0% higher, RR 1.53, p = 0.17, treatment 36 of 101 (35.6%), control 10 of 43 (23.3%).
Details of all 230 studies    Meta analysis
Please submit corrections, updates, or comments.
Submit